Literature DB >> 9974425

Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?

A M Heikkinen1, L Niskanen, M Ryynänen, M H Komulainen, M T Tuppurainen, M Parviainen, S Saarikoski.   

Abstract

Postmenopausal hormone replacement therapy (HRT) has favorable effects on the serum lipid profile, and it also decreases the risk of cardiovascular diseases. The apolipoprotein E genotype has influence on serum levels of lipids and lipoproteins; apoE allele epsilon4 (apoE4) is associated with high total and LDL cholesterol levels. Genotype also influences the lipid responses to treatment with diet and statins, but the effect of HRT in different apoE genotypes is unknown. We studied the effects of HRT on the concentrations of serum lipids in apoE4-positive early postmenopausal women (genotypes 3/4 and 4/4) compared with apoE4-negative women (genotypes 2/3 and 3/3) in a population-based, prospective 5-year study. In all, 232 early postmenopausal women were randomized into 2 treatment groups: an HRT group (n=116), which received a sequential combination of 2 mg estradiol valerate (E2Val) from day 1 to 21 and 1 mg cyproterone acetate (CPA) from day 12 to 21 (Climen), and a placebo group (n=116), which received 500 mg/d calcium lactate. Serum concentrations of total, LDL, and HDL cholesterol and triglycerides were measured at baseline and after 2 and 5 years of treatment. A total of 154 women completed the final analysis. During the follow-up period, serum total cholesterol and LDL cholesterol concentrations decreased in the HRT group in apoE4-negative women (8.1% and 17.1%, respectively; P<0.001) but did not change in the HRT group in apoE4-positive women or in the placebo group. Serum HDL cholesterol concentrations decreased in the placebo group (apoE4-negative, 3.9%, P=0.015; apoE4-positive, 8.1%, P=0.004) but did not change significantly in the HRT group. Serum triglyceride levels tended to increase in both study groups and genotypes (15.1% to 36.2%, P<0.038 to 0.001), but no differences were observed between the study groups or genotypes, respectively. Our finding was that in postmenopausal Finnish women LDL cholesterol levels in apoE4-negative subjects respond more favorably to HRT than those in apoE4-positive subjects. This finding has potential importance in postmenopausal women with hypercholesterolemia, if confirmed in other studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9974425     DOI: 10.1161/01.atv.19.2.402

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

1.  SNP-SNP interactions within APOE gene influence plasma lipids in postmenopausal osteoporosis.

Authors:  Monica Singh; Puneetpal Singh; Pawan Kumar Juneja; Surinder Singh; Taranpal Kaur
Journal:  Rheumatol Int       Date:  2010-03-26       Impact factor: 2.631

2.  Do long-term HDL-C declines associated with a first birth vary by apo E phenotype? The Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  Erica P Gunderson; Rachel A Whitmer; Cora E Lewis; Charles P Quesenberry; Delia Smith West; Stephen Sidney
Journal:  J Womens Health (Larchmt)       Date:  2005-12       Impact factor: 2.681

Review 3.  Pharmacogenetics of Lipid-lowering Therapies.

Authors:  Jose M Ordovas; Haiqing Shen
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

4.  Effects of apolipoprotein E genotype on blood cholesterol in adolescent girls.

Authors:  Janet E Fulton; Shifan Dai; Jo Anne Grunbaum; Eric Boerwinkle; Darwin R Labarthe
Journal:  Am J Prev Med       Date:  2009-07       Impact factor: 5.043

Review 5.  Pharmacogenetics of lipid diseases.

Authors:  Jose M Ordovas
Journal:  Hum Genomics       Date:  2004-01       Impact factor: 4.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.